Molecular Analysis for Gastro-Esophageal Cancer: Multicenter Discrete Choice Experiment

Gastric Cancer Clinical Trial

— MAGECmultiDiCE  

Official title:

Molecular Analysis for Gastro-Esophageal Cancer: Multicenter Discrete Choice Experiment

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT06346080
• Other study ID #: s68670
• Status: Not yet recruiting
• Phase: N/A
• Start date: August 1, 2024
• Est. completion date: August 1, 2026

Study information

• Verified date: March 2024
• Source: KU Leuven
• Contact: Stijn Vanstraelen, MD
• Phone: 16346822
• Email: stijn.vanstraelen[@]kuleuven.be
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The goal of this survey is to investigate the participants' preference for a specific screening/diagnostic tool to detect and assess gastro-esophageal cancer. The main question it aims to answer are: - Which diagnostic modality is preferred by patients and the general population? - Which features of the diagnostic test are most detrimental in the decision-making for one or the other modality? - Are geographical differences present in regard to the preference for a diagnostic modality? Participants will be asked to complete a survey of 20-25min, including a brief intake regarding their socio-economic status. This approach will allow us to correct for confounding factors.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 2200
• Est. completion date: August 1, 2026
• Est. primary completion date: August 1, 2026
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 85 Years

Eligibility

Inclusion Criteria:

1. Individuals >18yo to 75yo (upper age limit of Barrett's surveillance)

2. Access to computer or smartphone

3. Clear understanding of available languages of the experiment (English, French, Dutch, Spanish, German, Chinese, Japanese)

Exclusion Criteria:

1. Individuals less than 18yo and more than 75yo

2. Incarcerated individuals

Related Conditions & MeSH terms

• Esophageal Cancer
• Esophageal Neoplasms
• Gastric Cancer
• Stomach Neoplasms

Intervention

Other:
• Survey
Discrete choice survey

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
KU Leuven

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The rate of contribution of diagnostic features to the preference of participants	A part-worth analysis, expressed as percentage, from a discrete choice experiment (questionnaire) will assess the features that are most important to the participants	2 years
Primary	The percentage differences in preference of participants between geographical regions	Differences in preferences will be compared between different geographical regions using chi-squared or McNemar's test	2 years
Secondary	Assess the rate patient-level demographics influence the importance of a test feature, expressed as an odds ratio	Assess the influence of demographic characteristics on the decision-making process using a multivariable logistic regression model, providing odds ratios.	2 years
Secondary	Assess the rate of trade-off demonstrated as odds ratio between cancer-related mortality reduction and costs	Based on an anticipated cancer detection and cost, we will assess the willingness-to-pay using a multivariable logistic regression, providing odds ratios.	2 years